Cardiovascular Systems Inc. (NASDAQ:CSII)‘s stock had its “outperform” rating reiterated by equities research analysts at Leerink Swann in a research report issued on Tuesday. They currently have a $30.00 price objective on the medical device company’s stock. Leerink Swann’s price objective would suggest a potential upside of 10.54% from the stock’s current price.

CSII has been the subject of a number of other reports. Zacks Investment Research raised shares of Cardiovascular Systems from a “hold” rating to a “buy” rating and set a $25.00 price target for the company in a research note on Monday, October 31st. JMP Securities started coverage on shares of Cardiovascular Systems in a research note on Friday, October 7th. They set an “outperform” rating and a $35.00 price target for the company. Feltl & Co. raised shares of Cardiovascular Systems from a “buy” rating to a “strong-buy” rating and set a $30.00 price target for the company in a research note on Thursday, October 27th. Needham & Company LLC upped their target price on shares of Cardiovascular Systems from $23.00 to $27.00 and gave the company a “buy” rating in a research note on Thursday, August 4th. Finally, Bank of America Corp. raised shares of Cardiovascular Systems from an “underperform” rating to a “neutral” rating in a research note on Thursday, August 4th. One analyst has rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average price target of $27.50.

Analyst Recommendations for Cardiovascular Systems (NASDAQ:CSII)

Shares of Cardiovascular Systems (NASDAQ:CSII) opened at 27.14 on Tuesday. Cardiovascular Systems has a 52 week low of $7.50 and a 52 week high of $26.45. The firm’s market cap is $897.33 million. The firm’s 50 day moving average is $23.80 and its 200-day moving average is $20.67.

Cardiovascular Systems (NASDAQ:CSII) last posted its quarterly earnings results on Wednesday, October 26th. The medical device company reported ($0.06) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.19) by $0.13. The business earned $49.80 million during the quarter, compared to the consensus estimate of $205.50 million. Cardiovascular Systems had a negative net margin of 24.24% and a negative return on equity of 30.19%. Cardiovascular Systems’s revenue for the quarter was up 13.5% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.41) earnings per share. Equities research analysts predict that Cardiovascular Systems will post ($0.21) EPS for the current year.

In other news, Director Edward M. Brown sold 10,000 shares of the company’s stock in a transaction that occurred on Tuesday, November 15th. The shares were sold at an average price of $24.95, for a total value of $249,500.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Laura Gillund sold 1,395 shares of the company’s stock in a transaction that occurred on Monday, August 22nd. The shares were sold at an average price of $23.93, for a total transaction of $33,382.35. Following the completion of the transaction, the insider now owns 82,817 shares of the company’s stock, valued at approximately $1,981,810.81. The disclosure for this sale can be found here. 3.60% of the stock is currently owned by insiders.

A number of hedge funds and other institutional investors have recently made changes to their positions in CSII. BNP Paribas Arbitrage SA boosted its position in shares of Cardiovascular Systems by 39.4% in the third quarter. BNP Paribas Arbitrage SA now owns 5,445 shares of the medical device company’s stock valued at $129,000 after buying an additional 1,540 shares during the last quarter. Cutler Group LP boosted its position in shares of Cardiovascular Systems by 4.7% in the second quarter. Cutler Group LP now owns 7,787 shares of the medical device company’s stock valued at $143,000 after buying an additional 350 shares during the last quarter. Strs Ohio acquired a new position in shares of Cardiovascular Systems during the second quarter valued at approximately $194,000. Stratos Wealth Partners LTD. acquired a new position in shares of Cardiovascular Systems during the third quarter valued at approximately $215,000. Finally, Partner Investment Management L.P. acquired a new position in shares of Cardiovascular Systems during the third quarter valued at approximately $245,000. Institutional investors and hedge funds own 67.75% of the company’s stock.

Cardiovascular Systems Company Profile

Cardiovascular Systems, Inc is a medical technology company. The Company is engaged in treating patients suffering from peripheral and coronary artery diseases, including those with arterial calcium. The Company develops an orbital atherectomy technology for both peripheral and coronary commercial applications.

5 Day Chart for NASDAQ:CSII

Receive News & Stock Ratings for Cardiovascular Systems Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardiovascular Systems Inc. and related stocks with our FREE daily email newsletter.